ATE429915T1 - 5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie - Google Patents
5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemieInfo
- Publication number
- ATE429915T1 ATE429915T1 AT03808198T AT03808198T ATE429915T1 AT E429915 T1 ATE429915 T1 AT E429915T1 AT 03808198 T AT03808198 T AT 03808198T AT 03808198 T AT03808198 T AT 03808198T AT E429915 T1 ATE429915 T1 AT E429915T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- alkylene
- inhibitors
- acid derivatives
- treatment
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- 208000032928 Dyslipidaemia Diseases 0.000 title abstract 2
- 208000017170 Lipid metabolism disease Diseases 0.000 title abstract 2
- 230000003243 anti-lipolytic effect Effects 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 title 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 abstract 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003623 enhancer Substances 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 abstract 1
- KOPFEFZSAMLEHK-UHFFFAOYSA-N 1h-pyrazole-5-carboxylic acid Chemical class OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 abstract 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 229940123208 Biguanide Drugs 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract 1
- 229940123464 Thiazolidinedione Drugs 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003288 aldose reductase inhibitor Substances 0.000 abstract 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 abstract 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 abstract 1
- 150000004283 biguanides Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract 1
- 229940125753 fibrate Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940031439 squalene Drugs 0.000 abstract 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41805702P | 2002-10-10 | 2002-10-10 | |
| PCT/US2003/032174 WO2004032928A1 (en) | 2002-10-10 | 2003-10-09 | 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE429915T1 true ATE429915T1 (de) | 2009-05-15 |
Family
ID=32094143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03808198T ATE429915T1 (de) | 2002-10-10 | 2003-10-09 | 5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060167270A1 (de) |
| EP (1) | EP1551403B1 (de) |
| CN (1) | CN1720046A (de) |
| AT (1) | ATE429915T1 (de) |
| AU (1) | AU2003300014A1 (de) |
| CA (1) | CA2501134A1 (de) |
| DE (1) | DE60327446D1 (de) |
| WO (1) | WO2004032928A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004083388A2 (en) | 2003-03-14 | 2004-09-30 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| WO2005011677A1 (en) * | 2003-06-13 | 2005-02-10 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases |
| PE20050483A1 (es) * | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
| AU2004293415A1 (en) | 2003-11-21 | 2005-06-09 | Arena Pharmaceuticals, Inc. | 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof |
| JP2008519080A (ja) * | 2004-11-05 | 2008-06-05 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物 |
| PE20060949A1 (es) * | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| EP1899304A1 (de) * | 2005-05-23 | 2008-03-19 | Arena Pharmaceuticals, Inc. | 5-amino-1h-pyrazol-3-carbonsäurederivate als agonisten des g-protein-gekoppelten rezeptors (gpcr) rup38 zur behandlung von stoffwechselerkrankungen damit |
| CA2723424A1 (en) * | 2008-05-19 | 2009-11-26 | Burnham Institute For Medical Research | Intestinal alkaline phosphatase modulators and uses thereof |
| AR091739A1 (es) | 2012-07-11 | 2015-02-25 | Elcelyx Therapeutics Inc | Composiciones y metodos para reducir el riesgo cardiometabolico |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1048104A (en) * | 1963-03-04 | 1966-11-09 | Upjohn Co | Pharmaceutical compositions containing 3,5-disubstituted pyrazoles |
| GB1213162A (en) * | 1966-11-16 | 1970-11-18 | Astra Ab | Serum lipid lowering pyridine derivatives and their preparation |
| DE2439137A1 (de) * | 1974-08-14 | 1976-08-12 | Wuelfing J A Fa | 3-methyl-pyrazol-5-carboxylate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate |
| DE2517229A1 (de) * | 1975-04-18 | 1976-10-28 | Boehringer Mannheim Gmbh | Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung |
| US4282361A (en) * | 1978-03-16 | 1981-08-04 | Massachusetts Institute Of Technology | Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines |
| US5464860A (en) * | 1988-11-30 | 1995-11-07 | Novapharme | N(pyrazol-3-yl) benzamides and pharmaceutical compositions |
| US6200980B1 (en) * | 1995-06-07 | 2001-03-13 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl purinone derivatives |
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| US6444816B1 (en) * | 1997-10-27 | 2002-09-03 | Dr. Reddy's Research Foundation | Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof |
| US6369067B1 (en) * | 1997-10-27 | 2002-04-09 | Dr. Reddy's Research Foundation | Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| US7718692B2 (en) * | 2004-02-13 | 2010-05-18 | Carson John R | Hetero-substituted acetanilide derivatives as analgesic agents |
| US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| US7745630B2 (en) * | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| CA2551952A1 (en) * | 2003-12-29 | 2005-07-21 | Sepracor Inc. | Pyrrole and pyrazole daao inhibitors |
-
2003
- 2003-10-09 CA CA002501134A patent/CA2501134A1/en not_active Abandoned
- 2003-10-09 US US10/530,902 patent/US20060167270A1/en not_active Abandoned
- 2003-10-09 AU AU2003300014A patent/AU2003300014A1/en not_active Abandoned
- 2003-10-09 CN CN200380105221.5A patent/CN1720046A/zh active Pending
- 2003-10-09 EP EP03808198A patent/EP1551403B1/de not_active Expired - Lifetime
- 2003-10-09 AT AT03808198T patent/ATE429915T1/de not_active IP Right Cessation
- 2003-10-09 WO PCT/US2003/032174 patent/WO2004032928A1/en not_active Ceased
- 2003-10-09 DE DE60327446T patent/DE60327446D1/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003300014A1 (en) | 2004-05-04 |
| EP1551403A1 (de) | 2005-07-13 |
| DE60327446D1 (de) | 2009-06-10 |
| CN1720046A (zh) | 2006-01-11 |
| EP1551403B1 (de) | 2009-04-29 |
| WO2004032928A1 (en) | 2004-04-22 |
| CA2501134A1 (en) | 2004-04-22 |
| US20060167270A1 (en) | 2006-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004033431A3 (en) | Hydroxypyrazoles for use against metabolic-related disorders | |
| EA200701361A1 (ru) | Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ | |
| DE602005024279D1 (de) | 5-substituierte-2-phenylaminobenzamide als mek-inhibitoren | |
| PE20060150A1 (es) | Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion | |
| PE20090649A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
| ATE253545T1 (de) | Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren | |
| TW200738698A (en) | Organic compounds | |
| RU2007108861A (ru) | Трифтометилзамещенные бензамиды в качестве ингибиторов киназ | |
| PE20091725A1 (es) | Activadores piridazinona de la glucoquinasa | |
| TNSN06150A1 (en) | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | |
| ATE429915T1 (de) | 5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie | |
| WO2007006534A3 (en) | Piperidine derivatives useful in the diagnostic and therapeutic treatment of diseases depending on renin activity | |
| JP5765738B2 (ja) | ロスバスタチンおよびアトルバスタチン誘導体 | |
| NO20070972L (no) | Benzyloksyderivater som MAOB-inhibitorer | |
| WO2005051937A3 (en) | 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof | |
| TNSN08287A1 (en) | 3,5-substituted piperidine compounds as renin inhibitors | |
| RU2008129623A (ru) | Ингибиторы ccr9 активности | |
| JP5738205B2 (ja) | アトルバスタチンラクトールの薬物としての使用 | |
| UA90878C2 (ru) | Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ | |
| TH82141A (th) | สารอนุพันธ์เตตราโซล และวิธีการของการบำบัดความผิดปกติที่เกี่ยวข้องกับกระบวนการเมแทบอลิซึมของสารเหล่านั้น | |
| SE9904416D0 (sv) | Crystalline form | |
| NZ602412A (en) | Substituted gamma lactams as therapeutic agents | |
| CN1898198A (zh) | 作为缓激肽拮抗剂或反向激动剂的α－羟基酰胺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |